Intellectual Property
API believes that its intellectual property (IP) is a key to the Company’s success.  API’s IP estate includes 17 U.S.  and 51 international both issued and pending patents which the Company believes will present barriers to entry, in addition to other barriers inherent in the radiopharmaceutical sector, to would-be competitors.  The Company’s IP consists of issued patents, pending patent applications and know-how that includes knowledge of existing isotope supply chains and hands on experience and expertise of the Company’s key collaborators and consultants.
In addition to its own internally generated IP, API in-licenses patents and patent applications from its research and development collaborators and other organizations.  

Within the Company’s IP portfolio, there are several groups of issued and applied for patents:

  • Platform technology patents: are broad patents that cover use of alpha emitting isotopes Ac-225 and Bi-213 for treatment of patients with any type of cancer.  These are the core of API’s IP portfolio.
  • Drug preparation method patents: pertain to highly specialized methods to produce APIT based drugs.
  • Drug components related patents:there are three key components of APIT based drugs: isotope (Ac-225 or Bi-213); chelator (DTPA or DOTA); and mAbs (specific for each type of cancer).  Therefore, these patents can be classified into three sub-groups:
    - Isotope production patents (cyclotron patents)
    - Chelator composition patents
    - mAb composition and production patents (in-licensed from partners)
  • Method of treatment patents: these relate to specific methods of treatment related to APIT, like e.g.  methods to improve safety of treatment with APIT based drugs

API is continuously working on enhancing its IP portfolio, including notably initiatives to strengthen its intellectual property related to cyclotron based production of Ac-225.  The Company’s IP counsel is WilmerHale, an international law firm with offices in 13 cities in the United States, Europe and Asia.  Below is presented a brief overview of the key API’s patents and patent groups:

Actinium Pharmaceuticals Intellectual Property Portfolio Overview